{"page":{"totalFilteredElements":25},"studies":[{"active":true,"description":"<p class=\"MsoNormal\">A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants with Advanced Solid Tumors<br /></p><p class=\"MsoNormal\">EUDRA-CT Nummer ge&#228;ndert 18.12.2023<br /></p><p class=\"MsoNormal\">von 2021-001188-26 auf&#160; 2023-503651-10-00<br /></p>","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T13:04:26+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of \nBMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung \nCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies","eudractNumber":"2024-519814-29","id":10710,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"EGFR","id":"mt_1"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF","id":"mt_9"},{"name":"ALK","id":"mt_11"},{"name":"ROS-1 (c-ros oncogene 1, receptor tyrosine kinase)","id":"mt_12"},{"name":"HER2/neu","id":"mt_19"},{"name":"RET (Rezeptor-Tyrosinkinase)","id":"mt_76"},{"name":"NTRK","id":"mt_81"}],"nctNumber":"NCT06855771","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-12T13:04:34+02:00","shortTitle":"BMS-CA240-0009","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"A Phase 2\nOpen-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination\nwith Other Agents in Participants with Advanced and/or Metastatic Solid Tumors\nwith Homozygous MTAP Deletion","eudractNumber":"2025-524285-18","id":11869,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"MTAP (methylthioadenosine phosphorylase)","id":"mt_260"}],"nctNumber":"NCT07492680","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-10-14T13:30:01+02:00","shortTitle":"BZKF BMS CA240-005","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Ver&#228;nderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T10:53:49+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p style=\"margin:0cm;margin-bottom:.0001pt;\">A phase 2b, randomized, blinded,\nplacebo-controlled trial investigating the efficacy and safety of visugromab\nversus placebo, both in combination with pembrolizumab, pemetrexed, and\ncis-/carboplatin, in participants with newly diagnosed metastatic non-squamous\nnon-small cell lung cancer (GDFATHER-LUNG-01)</p>","eudractNumber":"2024-516792-32","id":10166,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07098988","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-01-14T09:32:05+01:00","shortTitle":"Catalym CTL-002-003 GDFATHER-LUNG-01","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 2b, randomized, blinded, placebo-controlled trial investigating the efficacy of visugromab plus nivolumab in combination with docetaxel versus docetaxel alone in metastatic non-squamous non-small-cell lung cancer (nsq-NSCLC) after failing one prior line of systemic treatment containing a checkpoint inhibitor for advanced/metastatic nsq-NSCLC","eudractNumber":"2024-516794-70","id":10165,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07246863","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-02-24T09:19:02+01:00","shortTitle":"Catalym CTL-002-004 GDFATHER-LUNG-02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)","eudractNumber":"2022-001822-31","id":10150,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-01-07T08:54:18+01:00","shortTitle":"DuCoRa-SCLC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non&#8722;small cell lung cancer","eudractNumber":"2024-518365-10-00","id":11679,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06793215","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T09:34:31+01:00","shortTitle":"KRAScendo 2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive NIS zu klinischen Outcomes bei Patienten mit fortgeschrittenem nicht kleinzelligem Lungenkrebs (NSCLC) mit EGFR Mutation unter Behandlung mit zugelassenem Amivantamab-haltigen Therapieschemata im Rahmen der standardm&#228;&#223;igen klinischen Praxis","eudractNumber":null,"id":11841,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T13:02:53+01:00","shortTitle":"Lepidoptera","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive nicht-interventionelle Studie (NIS) zur Untersuchung der Wirksamkeit von Tremilimumab &amp; Durvalumab + platinbasierter Chemotherapie (TDC) in Patient:innen mit metastasiertem nicht-plattenepithelialem NSCLC und Risikomutationen.","eudractNumber":null,"id":11012,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"TP53","id":"mt_24"},{"name":"KEAP1 (Kelch-like ECH-associated protein 1)","id":"mt_251"},{"name":"STK11 (Serine/threonine kinase 11)","id":"mt_253"}],"nctNumber":"NCT06494540","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2025-02-04T11:09:21+01:00","shortTitle":"NAUTIC","therapeutical":false,"therapyLines":[]}]}